Navigation Links
Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
Date:9/25/2007

ce-daily oral dosing.

EPOC (Endothelin A Proof Of Concept) Phase II findings:

The primary endpoint of the study was Progression-Free Survival (PFS) and a secondary endpoint was Overall Survival (OS). The PFS data did not show a statistically significant difference between ZD4054 and placebo treatment arms. However, preliminary survival data suggested an improvement in overall survival. The Phase II data presented today show that, at further follow-up, patients who received ZD4054 10mg once daily experienced a 45 percent reduction in the risk of death compared to placebo (HR 0.55; 80 percent CI 0.41, 0.73), translating into an improved median OS of 24.5 months with ZD4054 10mg once-daily compared with 17.3 months in the placebo arm.

Patients who received ZD4054 15mg once-daily experienced a 35 percent reduction in risk of death (HR 0.65; 80 percent CI 0.49, 0.86), again translating into an improved median OS of 23.5 months with ZD4054 15mg once-daily compared with 17.3 months in the placebo arm.

The OS results were as follows:

Intent-to-treat population ZD4054 15mg ZD4054 10mg Placebo
Number of patients 98 107 107
Number of deaths 34 33 51
Median overall survival (months) 23.5 24.5 17.3
Hazard ratio versus placebo 0.65 0.55
80 percent CI 0.49, 0.86 0.41, 0.73

It is usual to use PFS as an endpoint in Phase II studies, however it can be difficult to measure accurately in patients with metastatic HRPC. Overall survival is an unambiguous endpoint and clearly an important outcome for patients, commented Professor Nick James.

PFS in this study was measured through clinical or radiological evidence of disease worsening, or worsening of disease-related pain. However, patients with metastatic HRPC can typically have multiple bone metastases, making assessments of further changes in bone metastases difficult.

The EPOC data suggest that ZD4054 once-daily coul
'/>"/>

Contact: Aoife Gallagher
aoife_gallagher@uk.cohnwolfe.com
44-078-943-86422
Cohn & Wolfe Healthcare, London
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. SARS-Free Taiwan to Mark End Phase of Global Fight
3. S. Africa AIDS in death phase
4. Spray on contraceptive clears Phase I trial
5. Phase 3 trials of two multi-kinase inhibitors against cancer
6. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
7. Phase II trails of new HIV vaccine to be held in South Africa
8. Phase 1 Drug Trials on Humans to Be Made Public
9. Jalgaon: Third Phase Of Culling Operations Begin
10. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
11. Cadila to Commence Phase I Clinical Trials On ZYH2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... (PRWEB) July 14, 2014 The governments ... investment in the Global Mobile Health Solutions market. For ... the Health IT for Economic and Clinical Health Act ... 2009. , Analysts forecast the Global Mobile Health ... 34.88 percent over the period 2013-2018. According to the ...
(Date:7/14/2014)... July 14, 2014 The report ... Services [Physical Security, Life Safety, Facility Management], IT ... Forecast & Analysis (2014 - 2019)” defines and ... an in-depth analysis and forecasting of revenues. The ... various restraints and opportunities impacting it, along with ...
(Date:7/14/2014)... fitness may buffer some of the adverse health effects ... by researchers from the American Cancer Society, The Cooper ... in the journal Mayo Clinic Proceeding s, and ... and blood markers associated with cardiovascular disease is markedly ... behavior has been linked to an increase risk of ...
(Date:7/14/2014)... 14, 2014 This report provides ... in Americas. The analysis includes market size data ... and key company share data by revenue in ... and Mexico. It uses data and information sourced ... in-house analysis. , Scope,     Information ...
(Date:7/14/2014)... 2014 Secure Decisions, a leading provider ... with the Software Assurance Marketplace (SWAMP) to build a ... that drives everyday life. , The SWAMP, implemented by ... the Morgridge Institute for Research, is funded by the ... security practices by building a free facility with a ...
Breaking Medicine News(10 mins):Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 2Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 3Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 4Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3
... and Willing to ... 20s, - Boomers Can Stay On-the-Go with New ThermaCare(R) Arthritis HeatWraps ... percent of baby boomers claim they feel an average of 11 ... they are more,adventurous and willing to experiment now than when they ...
... guided trial design may increase probability of tumor response ... and accelerates ... (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned ... to its complete phase Ib trial of brostallicin used in ...
... CARLSBAD, Calif., Oct. 18 Isis,Pharmaceuticals, Inc. (Nasdaq: ... added a,new diabetes drug targeting the sodium dependent ... ISIS 388626, a generation 2.2,antisense drug that acts ... existing pipeline of drugs in development for the,treatment ...
... Lighted slippers for,those with troubled eyesight. A ... the player,s motions. Bowling equipment for those with ... One-stop online shopping for older adults and ... easier at Rehability! Your Optimal Living,Store, http://www.rehabilitystores.com ...
... Oct. 18 More than half of holiday shoppers ... to a good cause*. This,year, choose a gift that ... Alzheimer,s disease, the seventh leading cause of death,in the ... services for families struggling with,Alzheimer,s or support innovative research ...
... at US$26.00 Per Share -, VICTORIA, Oct. ... ; TSX: ASV) today announced that it has ... GALN) under which,Galenica, through a wholly-owned Canadian subsidiary, ... price of US$26.00 per share in cash. The,total ...
Cached Medicine News:Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 2Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 3Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 4Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 2Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 3Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 4Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 2Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 3Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 4Health News:Holiday Gifts for Those With Disabilities & Other Special Needs 2Health News:Holiday Gifts That Help Fight Alzheimer's Disease 2Health News:Aspreva to be Acquired by Galenica For US$915 Million 2Health News:Aspreva to be Acquired by Galenica For US$915 Million 3Health News:Aspreva to be Acquired by Galenica For US$915 Million 4Health News:Aspreva to be Acquired by Galenica For US$915 Million 5
(Date:7/14/2014)... 2014  More than any other generation, Millennials born in ... -- but their eyes don,t. These mobile devices demand a ... the eye has not evolved to cope with them. The ... do comfortably often results in tired eyes, focusing problems, headaches ... Strain. Now ZEISS has invented a new type of lens ...
(Date:7/14/2014)... July 14, 2014  Today, ATS Labs, Inc. (ATS), ... acquired the assets of MicroTest Labs, Inc. (MTL) of ... MTL is the first step in the strategy of ... platform to support the medical device and biopharmaceutical industries. ... Accuratus Lab Services , a name that personifies the ...
(Date:7/14/2014)... , July 14, 2014  Mallinckrodt plc (NYSE: ... QCOR ) today announced that the registration statement on Form ... by Mallinckrodt plc on May 16, 2014 and amended on ... Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, ... on Form S-4 is available on the SEC,s EDGAR system, ...
Breaking Medicine Technology:New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7
... and women infected with HIV reduced the risk of ... of oral antiretroviral therapy (ART), according to findings from ... Prevention Trials Network (HPTN), a global partnership dedicated to ... and structural interventions. The study, known ...
... May 12, 2011 Alma Lasers Ltd., a ... aesthetic treatment devices, today announced the launch of ... for aesthetic fractional laser resurfacing. ... iPixelEr—each feature Alma,s roller-style technology which delivers fast, ...
Cached Medicine Technology:Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052) 2Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052) 3Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052) 4Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052) 5Alma Lasers Introduces the iPixel Fractional Ablative Technology 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... ThumbFit™ reduces joint instability without disturbing ... remarkably comfortable and easy for users ... CHT and Robert V. Sypher Jr., ... in response to patients' complaints of ...
... the MP joint and the CMC joint of the ... both of the thumb joints. An excellent choice for ... who need maximum mobility for daily activities. Ideal for ... and for those with pain due to repetitive stress. ...
... molded from rigid plastic in a distinctive design ... comfort. The uniquely sculpted distal trim line ... maximum function of the hand. This is ... and sprains of the MCP joint, basal joint ...
Medicine Products: